[go: up one dir, main page]

BR0011419A - Derivados de etanossulfonil-piperidina - Google Patents

Derivados de etanossulfonil-piperidina

Info

Publication number
BR0011419A
BR0011419A BR0011419-7A BR0011419A BR0011419A BR 0011419 A BR0011419 A BR 0011419A BR 0011419 A BR0011419 A BR 0011419A BR 0011419 A BR0011419 A BR 0011419A
Authority
BR
Brazil
Prior art keywords
disease
neurodegeneration
diseases
compounds
piperidine derivatives
Prior art date
Application number
BR0011419-7A
Other languages
English (en)
Inventor
Alexander Alanime
Serge Burner
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Georg Jaeschke
Emmanuel Pinard
Rene Wyler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0011419A publication Critical patent/BR0011419A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/54—Sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/42—Oxygen atoms attached in position 3 or 5

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Patente de Invenção: "DERIVADOS DE ETANOSSULFONIL-PIPERIDINA". A invenção refere-se a compostos de fórmula geral (I) em que R significa hidrogênio ou hidróxi; R^ 2^ significa hidrogênio ou metila; e X significa -O- ou -CH~ 2~-; e seus sais de adição de ácido farmaceuticamente aceitáveis. Mostrou-se que esses compostos apresentam uma boa afinidade a receptores de NMDA e são, portanto, úteis no tratamento de doenças, onde as indicações terapêuticas incluem formas agudas de neurodegeneração causadas, por exemplo, por insulto ou traumatismo craniano; formas crónicas de neurodegeneração tais como doença de Alzheimer, doença de Parkinson, doença de Huntington ou EAL (esclerose amiotrópica lateral); neurodegeneração associada a infecções bacterianas ou virais, e, doenças tais como esquizofrenia, ansiedade, depressão e dores crónicas/agudas.
BR0011419-7A 1999-06-08 2000-05-31 Derivados de etanossulfonil-piperidina BR0011419A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99111126 1999-06-08
PCT/EP2000/004953 WO2000075109A1 (en) 1999-06-08 2000-05-31 Ethanesulfonyl-piperidine derivatives

Publications (1)

Publication Number Publication Date
BR0011419A true BR0011419A (pt) 2002-02-26

Family

ID=8238316

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0011419-7A BR0011419A (pt) 1999-06-08 2000-05-31 Derivados de etanossulfonil-piperidina

Country Status (38)

Country Link
US (1) US6310213B1 (pt)
EP (1) EP1189886B1 (pt)
JP (1) JP3645856B2 (pt)
KR (1) KR100571162B1 (pt)
CN (1) CN1142141C (pt)
AR (1) AR024282A1 (pt)
AT (1) ATE315025T1 (pt)
AU (1) AU770787B2 (pt)
BR (1) BR0011419A (pt)
CA (1) CA2376091C (pt)
CO (1) CO5160328A1 (pt)
CZ (1) CZ299483B6 (pt)
DE (1) DE60025348T2 (pt)
DK (1) DK1189886T3 (pt)
EG (1) EG26101A (pt)
ES (1) ES2254183T3 (pt)
GC (1) GC0000256A (pt)
GT (1) GT200000089A (pt)
HK (1) HK1046412B (pt)
HR (1) HRP20010885B1 (pt)
HU (1) HU228591B1 (pt)
IL (2) IL146750A0 (pt)
JO (1) JO2260B1 (pt)
MA (1) MA26797A1 (pt)
MX (1) MXPA01012585A (pt)
MY (1) MY128818A (pt)
NO (1) NO320613B1 (pt)
PA (1) PA8496601A1 (pt)
PE (1) PE20010218A1 (pt)
PL (1) PL196053B1 (pt)
RS (1) RS50033B (pt)
RU (1) RU2242464C2 (pt)
SI (1) SI1189886T1 (pt)
TN (1) TNSN00125A1 (pt)
TR (1) TR200103532T2 (pt)
TW (1) TWI254043B (pt)
WO (1) WO2000075109A1 (pt)
ZA (1) ZA200109706B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2225330T3 (es) * 2000-03-22 2005-03-16 Hoffmann La Roche Compuesto de piperidina y piperacina para empleo en el tratamiento de alzheimer.
DE60105144T2 (de) * 2000-04-20 2005-09-08 F. Hoffmann-La Roche Ag Pyrrolidin und piperidin derivate für die behandlung von neurodegenerativen erkrankungen
PA8525601A1 (es) * 2000-08-21 2002-04-25 Hoffmann La Roche Profarmacos de (3s,4s)-4-bencil-1-[2-(4-hidroxi-bencenosulfonil)-etil]-piperidin-3-ol
EP1332363A4 (en) * 2000-10-09 2007-08-29 Kay Double PROOF OF NEURODEGENERATIVE DISEASES
US6951875B2 (en) 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
US7005432B2 (en) * 2002-05-16 2006-02-28 Hoffman-La Roche Inc. Substituted imidazol-pyridazine derivatives
EP2254580A1 (en) * 2008-03-27 2010-12-01 EVOTEC Neurosciences GmbH Methods for treating disorders using nmda nr2b-subtype selective antagonist
WO2013012871A1 (en) * 2011-07-18 2013-01-24 Adolor Corporation Processes for the preparation of peripheral opioid antagonist compounds and intermediates thereto
TW202442646A (zh) * 2023-04-20 2024-11-01 大陸商紐歐申醫藥（上海）有限公司 含氮雜環類化合物及其製備方法和應用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4410822A1 (de) * 1994-03-24 1995-09-28 Schering Ag Neue Piperidin-Derivate
ZA9610745B (en) * 1995-12-22 1997-06-24 Warner Lambert Co 4-Subsituted piperidine analogs and their use as subtype selective nmda receptor antagonists
TW498067B (en) * 1996-07-19 2002-08-11 Hoffmann La Roche 4-hydroxy-piperidine derivatives

Also Published As

Publication number Publication date
US6310213B1 (en) 2001-10-30
HUP0201916A3 (en) 2003-05-28
ATE315025T1 (de) 2006-02-15
JO2260B1 (en) 2004-10-07
AU770787B2 (en) 2004-03-04
CN1354745A (zh) 2002-06-19
TR200103532T2 (tr) 2002-05-21
HK1046412B (zh) 2004-07-09
ES2254183T3 (es) 2006-06-16
WO2000075109A1 (en) 2000-12-14
HU228591B1 (hu) 2013-04-29
KR20020008850A (ko) 2002-01-31
PL352723A1 (en) 2003-09-08
TWI254043B (en) 2006-05-01
PL196053B1 (pl) 2007-11-30
PA8496601A1 (es) 2001-12-14
IL146750A0 (en) 2002-07-25
DK1189886T3 (da) 2006-05-15
CZ20014349A3 (cs) 2002-05-15
HRP20010885B1 (en) 2010-07-31
NO320613B1 (no) 2005-12-27
DE60025348T2 (de) 2006-08-24
IL146750A (en) 2006-12-10
MXPA01012585A (es) 2002-04-10
CA2376091C (en) 2006-03-14
AR024282A1 (es) 2002-09-25
EP1189886A1 (en) 2002-03-27
RU2242464C2 (ru) 2004-12-20
PE20010218A1 (es) 2001-02-28
AU5218100A (en) 2000-12-28
JP2003501415A (ja) 2003-01-14
KR100571162B1 (ko) 2006-04-17
NO20015920D0 (no) 2001-12-04
EP1189886B1 (en) 2006-01-04
CN1142141C (zh) 2004-03-17
NO20015920L (no) 2001-12-04
MY128818A (en) 2007-02-28
SI1189886T1 (sl) 2006-04-30
YU86501A (sh) 2004-09-03
DE60025348D1 (de) 2006-03-30
GC0000256A (en) 2006-11-01
MA26797A1 (fr) 2004-12-20
ZA200109706B (en) 2003-02-26
HRP20010885A2 (en) 2004-02-29
RS50033B (sr) 2008-11-28
TNSN00125A1 (fr) 2005-11-10
CZ299483B6 (cs) 2008-08-13
CO5160328A1 (es) 2002-05-30
GT200000089A (es) 2001-11-29
EG26101A (en) 2013-02-17
HUP0201916A2 (en) 2002-10-28
HK1046412A1 (en) 2003-01-10
JP3645856B2 (ja) 2005-05-11
CA2376091A1 (en) 2000-12-14

Similar Documents

Publication Publication Date Title
BR0116216A (pt) Inibidores de girase e seus usos
BR0015624A (pt) Uso de um composto, composto, composição farmacêutica, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0312729A (pt) Novos derivados de indol-3-enxofre
BR112012008518A2 (pt) derivado heterocíclico, e, composição farmacêutica
BR0314393A (pt) Piperazinas heterocìclicas substituìdas para o tratamento de esquizofrenia
BR0108610A (pt) Compostos azapolicìclicos condensados com arila
NZ527123A (en) Oxazolyl-pyrazole derivatives as kinase inhibitors
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BR0210711A (pt) Uso de um composto, composição farmacêutica, composto, e, processo para a preparação de um composto
BR0110233A (pt) 4-benzil-1-[2-(4-hidróxi-fenóxi)-etil]-piperidina-3,4-diol
BR0211742A (pt) Derivados de aminoisoxazole ativos como inibidores de cinase
BRPI0413860A (pt) [1,8]naftiridin-2-onas e compostos relacionados para o tratamento de esquizofrenia
BR0112395A (pt) Derivados de benzotiazol
UY30426A1 (es) Derivados sustituidos del 3-(4-metoxi-fenil)-3h-isoindol-1-ilamina trifluoroacetado, sus sales o solvatos farmaceuticamente aceptables, formulaciones farmacéuticas y aplicaciones.
BRPI0408990A (pt) derivados de pirimidin-4-ona e sua utilização como moduladores da p38-cinase
BR0010555A (pt) Inibidores de neuraminidases
BRPI0416989A (pt) derivados aminopirazole como inibidores gsk-3
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0411891A (pt) pirazol[3,4-b]piridin-6-onas como inibidores de gsk-3
BR0210028A (pt) Agentes antibacterianos
BR0311177A (pt) (imidazol-1-il-metil)-piridazina como bloqueador de receptores de nmda
MX2007012146A (es) Amida-macrociclos v antibacterianos.
EE200200466A (et) 8,8a-dihürdroindeno[1,2-d]tiasooli derivaadid, mis on asendatud 8a-asendis, nende valmistamismeetodja kasutamine ravimitena, näiteks anorektiliste toimeainetena
BRPI0411122A (pt) pirazol[3,4-b]piridin-6-onas como inibidores gsk-3
BR0011419A (pt) Derivados de etanossulfonil-piperidina

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O E 13 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: A61K 31/445, C07D 211/14, C07D 211/30, C07D 211/42, A61P 25/00, A61P 25/16, A61P 25/18, A61P 25/24, A61P 25/28

Ipc: C07D 211/46 (2011.01), C07D 211/30 (2011.01), A61K